CytoSorbents Corporation has announced updates on its ongoing regulatory reviews for DrugSorb™-ATR, a breakthrough blood purification device designed to reduce bleeding severity in patients undergoing coronary artery bypass grafting surgery on the antiplatelet drug Brilinta®. The U.S. FDA has scheduled an appeal hearing for the company's requested supervisory review, aiming to resolve outstanding deficiencies in its De Novo Request by the end of August 2025. Concurrently, Health Canada issued a Notice of Refusal for the Medical Device License application, citing regulatory non-compliance. CytoSorbents plans to file a "Request for Reconsideration" by July 25, 2025, to directly address these issues. The company remains optimistic about bringing this critical therapy to market by the end of the year, pending successful regulatory outcomes in both the U.S. and Canada.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。